Drug Development · global
Programming mRNA to Recognize Tumors and Produce IL-12: Strand Begins Human Trial of Intravenous Therapy
The first patients have received STX-003, which aims to use intracellular genetic regulation to restrict where an immune-stimulating protein is expressed. Whether this design can combine systemic administration with safety is only beginning to be tested in humans.
Using the immune system to attack cancer often hinges on keeping stimulation where it is needed. Interleukin-12 (IL-12) strongly activates the immune system, but systemic toxicity has limited its therapeutic use. Strand Therapeutics announced on October 29 that the first patients had received STX-003 in the ASCENT-1 trial, beginning to test whether regulatory features built into mRNA can concentrate IL-12 production in tumors.
STX-003 is administered by intravenous infusion and uses lipid nanoparticles to encapsulate self-replicating mRNA carrying instructions to produce human IL-12. Information in the Australian New Zealand Clinical Trials Registry further specifies that the RNA contains microRNA target sequences. According to the company, its genetic circuit is designed to read existing intracellular microRNA signals, allowing tumor cells to express IL-12 while suppressing expression in healthy tissues.
This strategy extends control beyond the point at which the drug enters cells: alongside efforts to deliver RNA to tumors, it also attempts to determine which cells can follow the instructions to produce protein. However, “tumor selectivity” remains a design goal. News of the first patients receiving treatment does not yet demonstrate that this regulatory system can sufficiently prevent IL-12 expression in healthy tissues or reduce associated toxicity in humans.
The company described this milestone as part of the Phase 1 ASCENT-1 trial. The full study, registered as NCT07751042, is planned as a Phase 1/2, open-label, multicenter trial with a target enrollment of 220 participants. It includes dose-escalation and expansion cohorts for STX-003 alone and in combination with the PD-1 inhibitor pembrolizumab. The figure of 220 is the overall recruitment target, not the number of people who have received treatment.
The trial must first establish acceptable doses and risks. Its registered primary assessments include adverse events, serious adverse events, dose-limiting toxicities, and changes in laboratory values and vital signs. The study will also track how the drug behaves in the body and tumor responses, and examine tumor-infiltrating lymphocytes through biopsies for signs of changes in the local immune environment.
If safety permits, subsequent data can gradually clarify whether restricting where IL-12 is expressed can deliver sufficient anticancer activity, and whether the combination with pembrolizumab warrants further development. The current announcement provides no human safety or efficacy results for STX-003. The main purpose of this early, nonrandomized, open-label study remains to identify feasible doses and preliminary biological activity; it is not yet sufficient to determine whether the treatment is superior to existing therapies.